The Role of Cardiovascular MRI in Heart Failure and the Cardiomyopathies

Cardiology Clinics

Volumn 25, Issue 1, 2007, Pages 71-95

  White, James A ^a,b   Patel, Manesh R ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR FUNCTION; CHAGAS DISEASE; CLINICAL ASSESSMENT TOOL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONSTRICTIVE PERICARDITIS; DEFIBRILLATOR; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; ENDOCARDIAL FIBROELASTOSIS; FABRY DISEASE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IRON OVERLOAD; MEDICAL TECHNOLOGY; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RESTRICTIVE CARDIOMYOPATHY; REVIEW; RISK ASSESSMENT; SARCOIDOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; FIBROSIS; HEART FAILURE, CONGESTIVE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING, CINE; SENSITIVITY AND SPECIFICITY;

EID: 34247536323     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.02.003     Document Type: Review

References (117)

1. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 104 24 (2001) 2996-3007
2. Mahrholdt H., Wagner A., Judd R.M., et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 26 15 (2005) 1461-1474
3. Shah D.J., Judd R.M., Kim R., et al. In: Edelman R.R., Hesselink J.R., and Zlatkin M.B. (Eds). Clinical magnetic resonance imaging. 3rd edition (2006), Elsevier, New York
4. Reimer K.A., Lowe J.E., Rasmussen M.M., et al. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56 5 (1977) 786-794
5. Soriano C.J., Ridocci F., Estornell J., et al. Noninvasive diagnosis of coronary artery disease in patients with heart failure and systolic dysfunction of uncertain etiology, using late gadolinium-enhanced cardiovascular magnetic resonance. J Am Coll Cardiol 45 5 (2005) 743-748
6. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 15 (2000) 1077-1084
7. Cury R.C., Cattani C.A., Gabure L.A., et al. Diagnostic performance of stress perfusion and delayed-enhancement MR imaging in patients with coronary artery disease. Radiology 240 1 (2006) 39-45
8. Plein S., Greenwood J.P., Ridgway J.P., et al. Assessment of non-ST-segment elevation acute coronary syndromes with cardiac magnetic resonance imaging. J Am Coll Cardiol 44 11 (2004) 2173-2181
9. Paetsch I., Jahnke C., Wahl A., et al. Comparison of dobutamine stress magnetic resonance, adenosine stress magnetic resonance, and adenosine stress magnetic resonance perfusion. Circulation 110 7 (2004) 835-842
10. Wolff S.D., Schwitter J., Coulden R., et al. Myocardial first-pass perfusion magnetic resonance imaging: a multicenter dose-ranging study. Circulation 110 6 (2004) 732-737
11. Ishida N., Sakuma H., Motoyasu M., et al. Noninfarcted myocardium: correlation between dynamic first-pass contrast-enhanced myocardial MR imaging and quantitative coronary angiography. Radiology 229 1 (2003) 209-216
12. Sensky P.R., Samani N.J., Reek C., et al. Magnetic resonance perfusion imaging in patients with coronary artery disease: a qualitative approach. Int J Cardiovasc Imaging 18 5 (2002) 373-383 [discussion: 385-376]
13. Al-Saadi N., Nagel E., Gross M., et al. Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. Circulation 101 12 (2000) 1379-1383
14. Klem I., Heitner J.F., Shah D.J., et al. Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. J Am Coll Cardiol 47 8 (2006) 1630-1638
15. Bunce N.H., Lorenz C.H., Keegan J., et al. Coronary artery anomalies: assessment with free-breathing three-dimensional coronary MR angiography. Radiology 227 1 (2003) 201-208
16. Casolo G., Del Meglio J., Rega L., et al. Detection and assessment of coronary artery anomalies by three-dimensional magnetic resonance coronary angiography. Int J Cardiol 103 3 (2005) 317-322
17. Budoff M.J., Achenbach S., and Duerinckx A. Clinical utility of computed tomography and magnetic resonance techniques for noninvasive coronary angiography. J Am Coll Cardiol 42 11 (2003) 1867-1878
18. Lardo A.C., Abraham T.P., and Kass D.A. Magnetic resonance imaging assessment of ventricular dyssynchrony: current and emerging concepts. J Am Coll Cardiol 46 12 (2005) 2223-2228
19. Westenberg J.J., Lamb H.J., van der Geest R.J., et al. Assessment of left ventricular dyssynchrony in patients with conduction delay and idiopathic dilated cardiomyopathy: head-to-head comparison between tissue Doppler imaging and velocity-encoded magnetic resonance imaging. J Am Coll Cardiol 47 10 (2006) 2042-2048
20. Aletras A.H., and Wen H. Mixed echo train acquisition displacement encoding with stimulated echoes: an optimized DENSE method for in vivo functional imaging of the human heart. Magn Reson Med 46 3 (2001) 523-534
21. Burkett E.L., and Hershberger R.E. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 45 7 (2005) 969-981
22. McCrohon J.A., Moon J.C., Prasad S.K., et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108 1 (2003) 54-59
23. Wu E., Judd R.M., Vargas J.D., et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 357 9249 (2001) 21-28
24. Bello D., Shah D.J., Farah G.M., et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 108 16 (2003) 1945-1953
25. Nazarian S., Bluemke D.A., Lardo A.C., et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation 112 18 (2005) 2821-2825
26. Park S., Choi B.W., Rim S.J., et al. Delayed hyperenhancement magnetic resonance imaging is useful in predicting functional recovery of nonischemic left ventricular systolic dysfunction. J Card Fail 12 2 (2006) 93-99
27. Assomull R.G., Prasad S.K., Lyne J., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48 (2006) 1977-1985
28. Laissy J.P., Hyafil F., Feldman L.J., et al. Differentiating acute myocardial infarction from myocarditis: diagnostic value of early- and delayed-perfusion cardiac MR imaging. Radiology 237 1 (2005) 75-82
29. Friedrich M.G., Strohm O., Schulz-Menger J., et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 97 18 (1998) 1802-1809
30. Mahrholdt H., Goedecke C., Wagner A., et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109 10 (2004) 1250-1258
31. Mahrholdt H., Wagner A., Deluigi C.C., et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114 15 (2006) 1581-1590
32. Abdel-Aty H., Boye P., Zagrosek A., et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 45 11 (2005) 1815-1822
33. Laissy J.P., Messin B., Varenne O., et al. MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest 122 5 (2002) 1638-1648
34. De Cobelli F., Pieroni M., Esposito A., et al. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol 47 8 (2006) 1649-1654
35. Maron B.J., Gardin J.M., Flack J.M., et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery risk development in (young) adults. Circulation 92 4 (1995) 785-789
36. Moon J.C., Reed E., Sheppard M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43 12 (2004) 2260-2264
37. Rickers C., Wilke N.M., Jerosch-Herold M., et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 112 6 (2005) 855-861
38. Moon J.C., Fisher N.G., McKenna W.J., et al. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 90 6 (2004) 645-649
39. Pennell D.J., Sechtem U.P., Higgins C.B., et al. Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. Eur Heart J 25 21 (2004) 1940-1965
40. Sorajja P., Nishimura R.A., Ommen S.R., et al. Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr 19 6 (2006) 788-795
41. Choudhury L., Mahrholdt H., Wagner A., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40 12 (2002) 2156-2164
42. Soler R., Rodriguez E., Monserrat L., et al. Magnetic resonance imaging of delayed enhancement in hypertrophic cardiomyopathy: relationship with left ventricular perfusion and contractile function. J Comput Assist Tomogr 30 3 (2006) 412-420
43. Teraoka K., Hirano M., Ookubo H., et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 22 2 (2004) 155-161
44. Amano Y., Takayama M., Takahama K., et al. Delayed hyper-enhancement of myocardium in hypertrophic cardiomyopathy with asymmetrical septal hypertrophy: comparison with global and regional cardiac MR imaging appearances. J Magn Reson Imaging 20 4 (2004) 595-600
45. Jassal D.S., Chaithiraphan V., Neilan T.G., et al. Delayed contrast enhancement CMR imaging in apical hypertrophic cardiomyopathy. Int J Cardiol 113 2 (2006) e56-e57
46. Maron B.J., Wolfson J.K., Epstein S.E., et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 8 3 (1986) 545-557
47. Moon J.C., Mogensen J., Elliott P.M., et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 91 8 (2005) 1036-1040
48. Moon J.C., McKenna W.J., McCrohon J.A., et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 9 (2003) 1561-1567
49. van Dockum W.G., ten Cate F.J., ten Berg J.M., et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 43 1 (2004) 27-34
50. van Dockum W.G., Beek A.M., ten Cate F.J., et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 111 19 (2005) 2503-2508
51. McKenna W.J., Thiene G., Nava A., et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 71 3 (1994) 215-218
52. Tandri H., Castillo E., Ferrari V., et al. Magnetic resonance imaging of arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol 48 (2006) 2277-2284
53. Bomma C., Rutberg J., Tandri H., et al. Misdiagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol 15 3 (2004) 300-306
54. Tandri H., Calkins H., Nasir K., et al. Magnetic resonance imaging findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol 14 5 (2003) 476-482
55. Auffermann W., Wichter T., Breithardt G., et al. Arrhythmogenic right ventricular disease: MR imaging vs angiography. AJR Am J Roentgenol 161 3 (1993) 549-555
56. Sen-Chowdhry S., Prasad S.K., Syrris P., et al. Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: comparison with task force criteria and genotype. J Am Coll Cardiol 48 10 (2006) 2132-2140
57. Tandri H., Saranathan M., Rodriguez E.R., et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 45 1 (2005) 98-103
58. Giorgi B., Mollet N.R., Dymarkowski S., et al. Clinically suspected constrictive pericarditis: MR imaging assessment of ventricular septal motion and configuration in patients and healthy subjects. Radiology 228 2 (2003) 417-424
59. Francone M., Dymarkowski S., Kalantzi M., et al. Assessment of ventricular coupling with real-time cine MRI and its value to differentiate constrictive pericarditis from restrictive cardiomyopathy. Eur Radiol 16 4 (2006) 944-951
60. Masui T., Finck S., and Higgins C.B. Constrictive pericarditis and restrictive cardiomyopathy: evaluation with MR imaging. Radiology 182 2 (1992) 369-373
61. Newman L.S., Rose C.S., and Maier L.A. Sarcoidosis. N Engl J Med 336 17 (1997) 1224-1234
62. Sharma O.P., Maheshwari A., and Thaker K. Myocardial sarcoidosis. Chest 103 1 (1993) 253-258
63. Shammas R.L., and Movahed A. Sarcoidosis of the heart. Clin Cardiol 16 6 (1993) 462-472
64. Johns C.J., and Michele T.M. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 78 2 (1999) 65-111
65. Silverman K.J., Hutchins G.M., and Bulkley B.H. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 58 6 (1978) 1204-1211
66. Roberts W.C., McAllister Jr. H.A., and Ferrans V.J. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med 63 1 (1977) 86-108
67. Iwai K., Sekiguti M., Hosoda Y., et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 11 1 (1994) 26-31
68. Virmani R., Bures J.C., and Roberts W.C. Cardiac sarcoidosis: a major cause of sudden death in young individuals. Chest 77 3 (1980) 423-428
69. Smedema J.P., Snoep G., van Kroonenburgh M.P., et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45 10 (2005) 1683-1690
70. Tadamura E., Yamamuro M., Kubo S., et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR Am J Roentgenol 185 1 (2005) 110-115
71. Patel M., Cawley P., Heitner J.F., et al. Detection and prognostic significance of myocardial damage in patients with sarcoidosis using delayed-enhancement cardiac magnetic resonance. Circulation 114 Suppl II (2006) 408 [abstract]
72. Falk R.H., Comenzo R.L., and Skinner M. The systemic amyloidoses. N Engl J Med 337 13 (1997) 898-909
73. Falk R.H. Diagnosis and management of the cardiac amyloidoses. Circulation 112 13 (2005) 2047-2060
74. Kholova I., and Niessen H. Amyloid in the cardiovascular system: a review. J Clin Pathol 58 (2005) 125-133
75. Pellikka P.A., Holmes Jr. D.R., Edwards W.D., et al. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med 148 3 (1988) 662-666
76. Maceira A.M., Joshi J., Prasad S.K., et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111 2 (2005) 186-193
77. Perugini E., Rapezzi C., Piva T., et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 92 3 (2006) 343-349
78. White J., Patel M., Shah D.J., et al. Prognostic utility of delayed enhancement magnetic resonance imaging in patients with systemic amyloidosis and suspected cardiac involvement. Circulation 114 (2006) 679 [abstract]
79. Eng C.M., Germain D.P., Banikazemi M., et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8 9 (2006) 539-548
80. Moon J.C., Sachdev B., Elkington A.G., et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24 23 (2003) 2151-2155
81. Sachdev B., Takenaka T., Teraguchi H., et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105 12 (2002) 1407-1411
82. Moon J.C., Sheppard M., Reed E., et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 8 3 (2006) 479-482
83. Ries M., Clarke J.T., Whybra C., et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118 3 (2006) 924-932
84. Beer M., Weidemann F., Breunig F., et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 97 10 (2006) 1515-1518
85. Borgna-Pignatti C., Rugolotto S., De Stefano P., et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 850 (1998) 227-231
86. Olson L.J., Edwards W.D., McCall J.T., et al. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol 10 6 (1987) 1239-1243
87. Aldouri M.A., Wonke B., Hoffbrand A.V., et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 84 3 (1990) 113-117
88. Easley Jr. R.M., Schreiner Jr. B.F., and Yu P.N. Reversible cardiomyopathy associated with hemochromatosis. N Engl J Med 287 17 (1972) 866-867
89. Rahko P.S., Salerni R., and Uretsky B.F. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol 8 2 (1986) 436-440
90. *) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22 23 (2001) 2171-2179
91. * cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 18 1 (2003) 33-39
92. Tanner M.A., Galanello R., Dessi C., et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 8 3 (2006) 543-547
93. * cardiovascular magnetic resonance. Br J Haematol 127 3 (2004) 348-355
94. Jensen P.D., Jensen F.T., Christensen T., et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 101 11 (2003) 4632-4639
95. Ino T., Benson L.N., Freedom R.M., et al. Natural history and prognostic risk factors in endocardial fibroelastosis. Am J Cardiol 62 7 (1988) 431-434
96. De Letter E.A., and Piette M.H. Endocardial fibroelastosis as a cause of sudden unexpected death. Am J Forensic Med Pathol 20 4 (1999) 357-363
97. Raman S.V., Mehta R., Walker J., et al. Cardiovascular magnetic resonance in endocardial fibroelastosis. J Cardiovasc Magn Reson 7 2 (2005) 391-393
98. Alter P., and Maisch B. Endomyocardial fibrosis in Churg-Strauss syndrome assessed by cardiac magnetic resonance imaging. Int J Cardiol 108 1 (2006) 112-113
99. Petersen S.E., Selvanayagam J.B., Wiesmann F., et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol 46 1 (2005) 101-105
100. Ritter M., Oechslin E., Sutsch G., et al. Isolated noncompaction of the myocardium in adults. Mayo Clin Proc 72 1 (1997) 26-31
101. Oechslin E.N., Attenhofer Jost C.H., Rojas J.R., et al. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol 36 2 (2000) 493-500
102. Rochitte C.E., Oliveira P.F., Andrade J.M., et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J Am Coll Cardiol 46 8 (2005) 1553-1558
103. Bocchi E.A., Kalil R., Bacal F., et al. Magnetic resonance imaging in chronic Chagas' disease: correlation with endomyocardial biopsy findings and gallium-67 cardiac uptake. Echocardiography 15 3 (1998) 279-288
104. Baigent C., Burbury K., and Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 356 9224 (2000) 147-152
105. Mall G., Huther W., Schneider J., et al. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5 1 (1990) 39-44
106. Aoki J., Ikari Y., Nakajima H., et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 67 1 (2005) 333-340
107. Mark P.B., Johnston N., Groenning B.A., et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 69 10 (2006) 1839-1845
108. Bello D., Fieno D.S., Kim R.J., et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 45 7 (2005) 1104-1108
109. Yan A.T., Shayne A.J., Brown K.A., et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 114 1 (2006) 32-39
110. Packer M., Antonopoulos G.V., Berlin J.A., et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 141 6 (2001) 899-907
111. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343 20 (2000) 1445-1453
112. Schvartzman P.R., Srichai M.B., Grimm R.A., et al. Nonstress delayed-enhancement magnetic resonance imaging of the myocardium predicts improvement of function after revascularization for chronic ischemic heart disease with left ventricular dysfunction. Am Heart J 146 3 (2003) 535-541
113. Baks T., van Geuns R.J., Biagini E., et al. Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics. J Am Coll Cardiol 47 1 (2006) 40-44
114. McAlister F.A., Ezekowitz J.A., Wiebe N., et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 141 5 (2004) 381-390
115. Bleeker G.B., Kaandorp T.A., Lamb H.J., et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation 113 7 (2006) 969-976
116. White J., Yee R., Yuan X., et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dysynchrony. J Am Coll Cardiol 48 10 (2006) 1953-1960
117. Mollet N.R., Dymarkowski S., Volders W., et al. Visualization of ventricular thrombi with contrast-enhanced magnetic resonance imaging in patients with ischemic heart disease. Circulation 106 23 (2002) 2873-2876